TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31144547

Group type: EXPERIMENTAL
Intervention: Centrally obese participants
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Non-obese controls
Number of subjects: 1358
Study: 29337906

Group type: EXPERIMENTAL
Intervention: Specific collagen peptides (SCP) 5 g daily for 12 months
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 131
Study: 27553375

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir + Ribavirin
Number of subjects: 1952

Group type: COMPARATOR
Intervention: Illicit drug use during therapy
Number of subjects: 1952
Study: 24641790

Group type: EXPERIMENTAL
Intervention: QiShenYiQi dripping pills, Tongxinluo placebo and routine medication
Number of subjects: 160

Group type: COMPARATOR
Intervention: Tongxinluo capsules, QiShenYiQi placebo and routine medication
Number of subjects: 160
Study: 22607134

Group type: EXPERIMENTAL
Intervention: Combination therapy (prednisone, azathioprine, and NAC)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: NAC alone
Number of subjects: 155
Study: 21167397

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 14
Study: 17958153

Group type: EXPERIMENTAL
Intervention: dynQuest software for conducting PC- and Web-based trials
Number of subjects: 0
Study: 16219883

Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg once daily)
Number of subjects: 7599
Study: 11856076

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole once daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: 20 mg omeprazole once daily
Number of subjects: 70
Study: 10200010

Group type: EXPERIMENTAL
Intervention: Levalbuterol 0.31 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Levalbuterol 0.63 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Racemic albuterol 2.5 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 7475138

Group type: EXPERIMENTAL
Intervention: Acadesine (0.1 mg/kg per minute intravenous infusion over 7 hours, 5 micrograms/ml in cardioplegic solution)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Acadesine
Number of subjects: 821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study: 2324634

Group type: EXPERIMENTAL
Intervention: Cognitive modeling alone in the use of constraint-seeking questions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive modeling and verbalization in the use of constraint-seeking questions
Number of subjects: 60
Study: 313510

Group type: EXPERIMENTAL
Intervention: Lymphocyte surface markers combined with Lukes-Collins classification
Number of subjects: 107
Study: 30350893

Group type: EXPERIMENTAL
Intervention: Number of breaks in sitting time (classified by tertiles: <26 breaks/h; 26-39 breaks/h; >39 breaks/h)
Number of subjects: 266
Study: 28138133

Group type: EXPERIMENTAL
Intervention: Higher baseline free T3
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Higher baseline free T4
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Changes in free T3 and total T3 levels
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Baseline thyroid hormones
Number of subjects: 569
Study: 25968249

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B group (GAL-3 levels)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B group (ALT levels)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B group (GGT levels)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B group (Correlation between GAL-3 and ALT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Inactive HBV carriers group (GAL-3 levels)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Inactive HBV carriers group (ALT levels)
Number of subjects: 92
Study: 24046023

Group type: EXPERIMENTAL
Intervention: RPL group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Occupational exposure and unhealthy habits
Number of subjects: 68
Study: 21527028

Group type: EXPERIMENTAL
Intervention: Planning and problem-solving training
Number of subjects: 89

Group type: COMPARATOR
Intervention: Basic cognition training
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both interventions (Planning and problem-solving training and Basic cognition training)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Planning and problem-solving training and Basic cognition training
Number of subjects: 89
Study: 19121589

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Oral anti-vitamin-K agents (AVK)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) in patients with cancer
Number of subjects: 241

Group type: COMPARATOR
Intervention: Oral anti-vitamin-K agents (AVK) in patients with cancer
Number of subjects: 241
Study: 17966026

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg preoperatively and then twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 50
Study: 15017013

Group type: EXPERIMENTAL
Intervention: Leukocyte count
Number of subjects: 18558

Group type: EXPERIMENTAL
Intervention: Leukocyte count increase over baseline levels
Number of subjects: 18558
Study: 11465636

Group type: EXPERIMENTAL
Intervention: Fluoxetine (n=27)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nortriptyline (n=16)
Number of subjects: 43
Study: 9220235

Group type: EXPERIMENTAL
Intervention: 0.15% ganciclovir gel
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: 0.05% ganciclovir gel
Number of subjects: 104

Group type: COMPARATOR
Intervention: 3% acyclovir ointment
Number of subjects: 104
Study: 8285927

Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/d
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1006
Study: 2821790

Group type: EXPERIMENTAL
Intervention: Bromodeoxyuridine (BUdR) or iododeoxyuridine (IUdR) during high-dose brain irradiation (total radiation dose 65-70 Gy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients who completed planned treatment (48 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: BUdR versus IUdR, 12-h versus 24-h infusion schedule, degree of surgical resection, or sex
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Good performance status and age under 50 years
Number of subjects: 60
Study: 31931855

Group type: EXPERIMENTAL
Intervention: Diabetic Foot Guidance System (SOPeD) - exercises at home three times a week for 12 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Recommended foot care by international consensus with no foot exercises
Number of subjects: 62
Study: 30902613

Group type: EXPERIMENTAL
Intervention: Alectinib, 600 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib, 250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0
Study: 28335102

Group type: EXPERIMENTAL
Intervention: Multiplex Paclitaxel Emission Stent (MSCPM-II)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Covered Metal Stent (CMS)
Number of subjects: 72
Study: 25457735

Group type: EXPERIMENTAL
Intervention: Iodixanol 270 (270 mg I/mL), scanned using low tube voltage of 80 kVp, reconstructed with iterative reconstruction techniques (IRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iopromide 370 (370 mg I/mL), scanned using 100 kVp, reconstructed with filtered back projection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 100
Study: 24239203

Group type: EXPERIMENTAL
Intervention: Paclitaxel‐eluting balloon (PEB) + self‐expanding nitinol bare‐metal stent (BMS)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) + self‐expanding nitinol bare‐metal stent (BMS)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Paclitaxel‐eluting balloon (PEB) + BMS
Number of subjects: 104

Group type: COMPARATOR
Intervention: Percutaneous transluminal angioplasty (PTA) + BMS
Number of subjects: 104
Study: 22000927

Group type: EXPERIMENTAL
Intervention: Combined administration of PYY(3-36) and GLP-1(7-36 amide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiological effects following a meal
Number of subjects: 0
Study: 19891258

Group type: EXPERIMENTAL
Intervention: GaAIAS (780 nm) laser, applied in continuous mode, twice a week, for four weeks, with energy set to 25 J/cm2.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GaAIAS (780 nm) laser, applied in continuous mode, twice a week, for four weeks, with energy set to 60 J/cm2.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GaAIAS (780 nm) laser, applied in continuous mode, twice a week, for four weeks, with energy set to 105 J/cm2.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo applications simulating the same parameters as the treated groups.
Number of subjects: 60
Study: 16489525

Group type: EXPERIMENTAL
Intervention: Capsaicin infusion (40 microg/ml, 2.5 ml/min for 60 minutes)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mechanical distension
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (6 volunteers; 3 women; age 27.5 ± 5.9 years)
Number of subjects: 6
Study: 15486846

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (VAQTA; Merck), administered at weeks 0 and 24
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 10650680

Group type: EXPERIMENTAL
Intervention: Resistance training intervention utilizing elastic bands for 8 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 8873668

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 819

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 819
Study: 1403211

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Clonidine/naltrexone
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 62
Study: 6365849

Group type: EXPERIMENTAL
Intervention: Riboflavin supplement (15 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 30761648

Group type: EXPERIMENTAL
Intervention: MyCognition Quotient (MyCQ)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Cambridge Neuropsychological Automated Test Battery (CANTAB)
Number of subjects: 87
Study: 28335758

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) course for nursing students
Number of subjects: 181
Study: 25888158

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification (CBM) training with motivational support (MS)
Number of subjects: 120
Study: 23429175

Group type: EXPERIMENTAL
Intervention: Electromagnetic field real‐time system (EFRTS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 48
Study: 20980720

Group type: EXPERIMENTAL
Intervention: Electrocoagulation-enabled biopsy (EC+ group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional biopsy without electrocoagulation (EC- group)
Number of subjects: 160
Study: 19319449

Group type: EXPERIMENTAL
Intervention: Fortified human milk
Number of subjects: 40

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 40
Study: 17275926

Group type: EXPERIMENTAL
Intervention: Sucralfate (1g solution, swished and swallowed four times daily for 7 days)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Lactulose (1g solution, swished and swallowed four times daily for 7 days)
Number of subjects: 58
Study: 15534122

Group type: EXPERIMENTAL
Intervention: Surgical removal
Number of subjects: 225

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 225
Study: 12811010

Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 0
Study: 10344012

Group type: EXPERIMENTAL
Intervention: Antioxidant therapy; specific details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 7562419

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 10 U/kg i.v. bolus dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 100 U/kg i.v. bolus dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 500 U/kg i.v. bolus dose
Number of subjects: 10
Study: 2123240

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 89

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 89
Study: 7393824

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmethylclomipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clomipramine and desmethylclomipramine
Number of subjects: 0
Study: 6541546

Group type: EXPERIMENTAL
Intervention: Isometric exercise
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dynamic exercise
Number of subjects: 23
Study: 30205241

Group type: EXPERIMENTAL
Intervention: Dietary sodium reduction to <1500 mg daily counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27333897

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral (CB) depression prevention group
Number of subjects: 119

Group type: COMPARATOR
Intervention: Health education (HE) control group
Number of subjects: 119
Study: 24890531

Group type: EXPERIMENTAL
Intervention: Aldosterone blockade
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 22976626

Group type: EXPERIMENTAL
Intervention: Secondary alveolar bone grafting (SABG) during mixed dentition (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Tertiary alveolar bone grafting (TABG) during permanent dentition (n = 15)
Number of subjects: 31
Study: 20427052

Group type: EXPERIMENTAL
Intervention: Competent model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incompetent model
Number of subjects: 0
Study: 18551008

Group type: EXPERIMENTAL
Intervention: Heart rate controlled 12 week exercise program (arm-cycling at target lactate concentrations of 2.0 +/- 0.5 mmol/l)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sedentary activity (control group)
Number of subjects: 24
Study: 15786889

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) with TST screening
Number of subjects: 914

Group type: COMPARATOR
Intervention: Isoniazid preventive therapy (IPT) without TST screening
Number of subjects: 914
Study: 12875311

Group type: EXPERIMENTAL
Intervention: Custom-fit compression shorts
Number of subjects: 20
Study: 10595329

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Continuous conjugated equine estrogens + progestin
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 7566901

Group type: EXPERIMENTAL
Intervention: Small circular cosine grating with randomized location embedded in spatial noise, exposed for 33 to 533 ms in peripheral vision.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foveal search task with free eye movements and unlimited exposure time, with and without noise.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vertical cosine grating exposed for 500 ms, varying randomization range of aperture orientation in the fovea with and without noise.
Number of subjects: 0
Study: 1718476

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 30
Study: 7080502

Group type: EXPERIMENTAL
Intervention: Lumbodorsal technique of tumour nephrectomy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Transperitoneal technique of tumour nephrectomy
Number of subjects: 51
Study: 31714586

Group type: EXPERIMENTAL
Intervention: MK-2206 200 mg weekly (initial dose), reduced to 135 mg due to toxicity
Number of subjects: 37
Study: 31270967

Group type: EXPERIMENTAL
Intervention: Intravenous iron administration
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 27392481

Group type: EXPERIMENTAL
Intervention: CM plus WM therapy (Reduning Injection or Xiyanping Injection)
Number of subjects: 451

Group type: COMPARATOR
Intervention: WM therapy alone
Number of subjects: 451
Study: 27453366

Group type: EXPERIMENTAL
Intervention: Salivary pepsin measurement
Number of subjects: 50
Study: 24779746

Group type: EXPERIMENTAL
Intervention: Dentures with reduced dental arches (WSM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dentures with full dental arches (FDA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dentures with reduced dental arches (WSM) after adding second molars
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dentures with full dental arches (FDA) after removing second molars
Number of subjects: 20
Study: 22297674

Group type: EXPERIMENTAL
Intervention: 800 mg elemental calcium diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2000 mg elemental calcium diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased calcium intake
Number of subjects: 0
Study: 19664081

Group type: EXPERIMENTAL
Intervention: Motivational Care Planning (MCP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 49
Study: 17453536

Group type: EXPERIMENTAL
Intervention: Cardiac deaths < or =30 days
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Non-cardiac deaths < or =30 days
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: In-hospital deaths >30 days
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Survivors of initial hospitalization
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Systemic vascular resistance index among deaths < or =30 days
Number of subjects: 302
Study: 15177809

Group type: EXPERIMENTAL
Intervention: Bakker's Hemisphere-Specific Stimulation (n = 9)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Random presentation of stimuli in either visual hemifield (n = 7)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Centrally presented stimuli (n = 8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Central stimuli with fixed presentation time (1500 ms) (n = 6)
Number of subjects: 30
Study: 11346139

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate-based triple therapy (RAM group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Omeprazole-based triple therapy (OAM group)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both RAM and OAM groups
Number of subjects: 59
Study: 9927810

Group type: EXPERIMENTAL
Intervention: Addition of beta 2-glycoprotein I (GPI) to sera from lepromatous leprosy patients
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Addition of beta 2-glycoprotein I (GPI) to sera from borderline leprosy patients
Number of subjects: 140

Group type: COMPARATOR
Intervention: Comparison of aCL titres in skin smear positive vs bacteriologically negative patients
Number of subjects: 140
Study: 7922637

Group type: EXPERIMENTAL
Intervention: Static electromagnetic field stimulation of 12.5 mT, single stimulation for 3x3 minutes with one minute breaks.
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Static electromagnetic field stimulation (in stimulated group)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Repeated stimulation of static electromagnetic field
Number of subjects: 119
Study: 3147895

Group type: EXPERIMENTAL
Intervention: Transcutaneous oxygen pressure measurements during oxygen breathing (5 and 10 1 O2 min‐1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Transcutaneous oxygen pressure measurements
Number of subjects: 76
Study: 31521153

Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 33

Group type: COMPARATOR
Intervention: Microscopic technique
Number of subjects: 33
Study: 28690703

Group type: EXPERIMENTAL
Intervention: Traditional Thai massage
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Joint mobilization
Number of subjects: 120
Study: 25560821

Group type: EXPERIMENTAL
Intervention: Soy protein-based meal replacements (S; n=12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-soy protein-based meal replacements (NS; n=12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined groups (S and NS)
Number of subjects: 25
Study: 23815552

Group type: COMPARATOR
Intervention: Diskus (DK)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Elpenhaler (EH)
Number of subjects: 113
Study: 20036019

Group type: EXPERIMENTAL
Intervention: sugar‐free cocoa beverage
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: sugar‐sweetened cocoa beverage
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study: 19478294

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17109365

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Locoregional Anesthesia (LA)
Number of subjects: 186
Study: 15258452

Group type: COMPARATOR
Intervention: 3% ascorbic acid cream
Number of subjects: 25

Group type: COMPARATOR
Intervention: sodium ascorbyl-2-phosphate
Number of subjects: 25
Study: 11504009

Group type: EXPERIMENTAL
Intervention: Postevent questionnaire with manipulated overlap in narrative content, narrative structure, or environmental context
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with no specified intervention
Number of subjects: 0
Study: 9076466

Group type: EXPERIMENTAL
Intervention: Pre-operative blood haemoglobin concentration in the range of 100-129 g/l
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Including 76 patients with a first AMI before surgery
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Adjusted for impaired health status and age > or = 75 years, fluid absorption > or = 500 ml, and blood loss > or = 275 ml
Number of subjects: 811
Study: 8419003

Group type: EXPERIMENTAL
Intervention: Indobufen (100 mg b.i.d.)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 2939216

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 20
Study: 30716291

Group type: EXPERIMENTAL
Intervention: N2O-based cryoablation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Argon gas-based cryoablation
Number of subjects: 60